Tempus and Sanford Health Collaborate on Personalized Medicine Initiative

CHICAGO, Nov. 01, 2017 -- Tempus, a rapidly-growing technology company focused on collecting and integrating molecular and clinical data and Sanford Health, one of the largest health system in the nation will collaborate to identify targeted therapies and clinical trials for breast cancer patients.

As part of the collaboration, Sanford Health will collect the data, removing identifiable information to the patients before Tempus will analyze it. Tempus will then analyze the molecular and clinical data of breast cancer patients who are treated at Sanford Health, as well as provide next generation sequencing and analysis for certain cancer patients across subtypes.

“As we continue to strive to deliver the best care possible to our patients, it is important to learn as much as we can about their disease and treatments that may be best suited to them,” said David Pearce, PhD, executive vice president of innovation and research at Sanford Health. “Working with Tempus allows our researchers and clinicians to gather deeper insight into their patient’s cancer that should ultimately lead to more effective treatment.”

In oncology, and across healthcare more broadly, datasets are small and disorganized. In order to usher in the age of precision medicine, Tempus built a series of data pipelines to collect, cleanse, and analyze data, at scale, utilizing the most sophisticated technologies, including cloud-based platform, cluster computing, next generation sequencing, natural language processing and AI-assisted image recognition. These data pipelines in turn are powering a variety of clinical and research applications to drive clinical decision support and cutting edge academic research.

“Empowering physicians with useful data that can improve patient care is the sole focus of Tempus,” said Eric Lefkofsky, Founder and CEO at Tempus. “We look forward to working with researchers and physicians across the Sanford Health system in our shared pursuit of data-driven, personalized care.”

Tempus, founded in 2015, continues to expand its network of partners and is currently working with leading academic medical centers, NCI designated cancer centers, hospital networks and community oncologists across the United States. 

About Tempus:
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs).

About Sanford Health:
Sanford Health is an integrated health system headquartered in the Dakotas. It is one of the largest health systems in the nation with 45 hospitals and nearly 300 clinics in nine states and four countries. Sanford Health’s 28,000 employees, including more than 1,300 physicians, make it the largest employer in the Dakotas. Nearly $1 billion in gifts from philanthropist Denny Sanford have allowed for several initiatives, including global children's clinics, genomic medicine and specialized centers researching cures for type 1 diabetes, breast cancer and other diseases. For more information, visit sanfordhealth.org.

Clo Ewing
Director of Communications at Tempus
[email protected]